View clinical trials related to Postmenopausal Bone Loss.
Filter by:The investigators propose a 24 week clinical research trial (12 week observational period followed by 12 week MedSD intervention) with feasibility of diet adoption and markers of bone turnover as the primary outcomes.
To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to bisphosphonates.
The main purpose of this study is to see what levels of Bone Mineral Density post-menopausal women with breast cancer have, and to see if the level of Bone Mineral Density changes during a women's treatment after her surgery. This trial studies changes in Bone Mineral Density and markers of of bone activity in post-menopausal women receiving treatment for early stage breast cancer.
Women undergoing surgical menopause often experience marked menopausal side effects but are reluctant to use estrogen or other female hormones to ease the transition to menopause because of worries that the hormones may increase breast cancer risks. This study will evaluate tibolone in women experiencing surgical menopause to assess its effects on bone health, menopause symptoms and breast density.
The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects of arzoxifene on the uterus (womb) in postmenopausal women. - The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. - The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. - The safety of arzoxifene and any side effects that might be associated with its use.